Linked Data API

Show Search Form

Search Results

1701461
registered interest false more like this
date less than 2024-04-16more like thismore than 2024-04-16
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients with type 2 diabetes. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Ashley Dalton more like this
uin 22203 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.</p><p>We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN
22201 more like this
22202 more like this
question first answered
less than 2024-04-22T09:40:27.427Zmore like thismore than 2024-04-22T09:40:27.427Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4981
label Biography information for Ashley Dalton more like this
1689527
registered interest false more like this
date less than 2024-02-16more like thismore than 2024-02-16
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help stop disruption of the supply of (a) Ozempic, (b) Trulicity and (c) similar medicines. more like this
tabling member constituency Leeds North West more like this
tabling member printed
Alex Sobel more like this
uin 14426 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-21more like thismore than 2024-02-21
answer text <p>While the position has improved, there continues to be a global supply issue with glucagon-like peptide-1 receptor agonists (GLP-1 RA), including Trulicity (dulaglutide) and Ozempic (semaglutide). We have issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on the 3 January 2024, on how to manage patients requiring these medicines.</p><p>Our guidance is clear that GLP-1 RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose, and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and the Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.</p><p>We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help in ensuring that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN
14424 more like this
14425 more like this
question first answered
less than 2024-02-21T16:10:45.88Zmore like thismore than 2024-02-21T16:10:45.88Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4658
label Biography information for Alex Sobel more like this
1687858
registered interest false more like this
date less than 2024-02-06more like thismore than 2024-02-06
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) monitor the availability, (b) notify relevant stakeholders of shortages and (c) help ensure adequate supply of (i) Victoza and (ii) other medications for patients with diabetes. more like this
tabling member constituency Brighton, Pavilion more like this
tabling member printed
Caroline Lucas more like this
uin 13302 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-13more like thismore than 2024-02-13
answer text <p>We are aware of global supply issues with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) including Victoza (liraglutide), which are licensed for treating patients with type 2 diabetes. We have issued guidance in the form of a Medicine Supply Notification, addressing all GLP-1 RAs advising healthcare professionals on how to manage patients requiring these medicines. Further guidance has been issued through a National Patient Safety Alert which provides further background and clinical information and actions for providers. This guidance was futher updated on 3 January 2024.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. Supplies of Rybelsus (semaglutide) have been boosted to support demand from new patients with type 2 diabetes, alongside patients switching from Victoza injections.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-13T17:54:36.897Zmore like thismore than 2024-02-13T17:54:36.897Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
3930
label Biography information for Caroline Lucas more like this
1684187
registered interest false more like this
date less than 2024-01-22more like thismore than 2024-01-22
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask Secretary of State for Health and Social Care, what estimate she has made of the number of people with type 2 diabetes impacted by the GLP-1 shortage. more like this
tabling member constituency Darlington more like this
tabling member printed
Peter Gibson more like this
uin 10916 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-29more like thismore than 2024-01-29
answer text <p>Information on the number of people impacted by the glucagon-like peptide 1 (GLP-1) shortage is not held by the Department. There continues to be a global supply issue with some GLP-1 receptor agonists, but following the Department’s ongoing engagement with manufacturers, NHS England, the Medicines and Healthcare products Regulatory Agency and others operating in the supply chain, the overall supply position has improved, with additional stock being secured to boost availability of these medicines for patients.</p><p>We issued updated guidance to healthcare professionals, in the form of a National Patient Safety Alert, on 3 January 2024. This provides advice on how to manage patients requiring these medicines. Our guidance remains clear that GLP-1 receptor agonists that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be prescribed for weight loss.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-01-29T16:02:14.783Zmore like thismore than 2024-01-29T16:02:14.783Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4754
label Biography information for Peter Gibson more like this
1667631
registered interest false more like this
date less than 2023-11-07more like thismore than 2023-11-07
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of Ozempic pens for patients with type 2 diabetes. more like this
tabling member constituency Brentford and Isleworth more like this
tabling member printed
Ruth Cadbury more like this
uin 242 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-17more like thismore than 2023-11-17
answer text <p>We are aware of a supply issue with glucagon-like peptide 1 receptor agonist (GLP-1 RA) medicines, including Ozempic pens. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN 243 more like this
question first answered
less than 2023-11-17T12:35:15.343Zmore like thismore than 2023-11-17T12:35:15.343Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4389
label Biography information for Ruth Cadbury more like this
1666738
registered interest false more like this
date less than 2023-10-23more like thismore than 2023-10-23
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent steps he has taken mitigate the impact of shortages of (a) Ozempic, (b) Rybelsus, (c) Trulicity, (d) Victoza, (e) Saxenda, (f) Byetta and (g) Bydureon. more like this
tabling member constituency Birmingham, Edgbaston more like this
tabling member printed
Preet Kaur Gill more like this
uin 203902 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-26more like thismore than 2023-10-26
answer text <p>We are aware of a supply issue with GLP-1 RA medicines. This includes Ozempic, Rybelsus, Trulicity, Victoza, Saxenda, Byetta and Bydureon. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine while there are shortages and are keeping this under review as the situation evolves.</p>
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-26T08:37:24.893Zmore like thismore than 2023-10-26T08:37:24.893Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4603
label Biography information for Preet Kaur Gill more like this
1661136
registered interest false more like this
date less than 2023-09-18more like thismore than 2023-09-18
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he plans to undertake a review of guidance on the prescription of glucagon-like peptide 1 (GLP-1) agonists to patients with type 2 diabetes. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi more like this
uin 200010 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-16more like thismore than 2023-10-16
answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service in England, in line with its established methods and processes.</p><p>NICE’s guideline on the management of type 2 diabetes in adults states that if triple therapy with metformin and 2 other oral drugs is not effective, not tolerated or contraindicated, switching one drug for a glucagon-like peptide 1 agonist should be considered for people who meet the specified criteria.</p><p>NICE is currently updating the drug treatment section of this guideline, which it expects to publish in December 2024. NICE also published final draft guidance on 8 September 2023 which recommends tirzepatide for treating type 2 diabetes alongside diet and exercise in adults who meet the specified criteria. Final guidance on tirzepatide is expected in October 2023.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-16T13:29:48.587Zmore like thismore than 2023-10-16T13:29:48.587Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1660994
registered interest false more like this
date less than 2023-09-15more like thismore than 2023-09-15
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions he has had with international counterparts on addressing shortages medicines to treat type 2 diabetes. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi more like this
uin 199819 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-21more like thismore than 2023-09-21
answer text <p>The Department has established processes to manage disruption to medical products and protect patient care. Supply chains for medical products are complex, global, and highly regulated, making them vulnerable to a variety of shocks, including around manufacture failure, demand spikes, international trade activity and disruption to logistics. In this specific case of medicines to treat type 2 diabetes, we are aware of a global supply issue with glucagon-like peptide-1 receptor agonists which are licensed for treating patients with type 2 diabetes. Whilst no specific discussions have been had with international counterparts, we are committed to working with international partners on the broader supply agenda.</p><p>We are continuing to work closely with manufacturers of medicines to treat type 2 diabetes and others working in the supply chain to help ensure the continued supply for patients in the United Kingdom, for example by asking suppliers to expedite deliveries. Alongside, we have provided advice for healthcare professionals on how to manage patients requiring these medicines whilst there are in shortage and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p>
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-09-21T09:31:49.703Zmore like thismore than 2023-09-21T09:31:49.703Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1660728
registered interest false more like this
date less than 2023-09-14more like thismore than 2023-09-14
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number and proportion of people with type 2 diabetes who will be affected by the shortage of GLP1-RA medications. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi more like this
uin 199596 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-19more like thismore than 2023-09-19
answer text <p>The information requested is currently not held centrally. The Department is monitoring demand for GLP1-RA medication using prescriptions data from the NHS Business Services Authority.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-09-19T15:57:51.727Zmore like thismore than 2023-09-19T15:57:51.727Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1660807
registered interest false more like this
date less than 2023-09-14more like thismore than 2023-09-14
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to increase stocks of diabetes medication. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Paula Barker more like this
uin 199678 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-19more like thismore than 2023-09-19
answer text <p>We are aware of a supply issue with Ozempic. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine. Our guidance is clear that glucagon-like peptide 1 receptor agonist medicines, such as Ozempic, that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for patients in the UK, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p>
answering member constituency Colchester more like this
answering member printed Will Quince more like this
grouped question UIN 199679 more like this
question first answered
less than 2023-09-19T09:35:57.177Zmore like thismore than 2023-09-19T09:35:57.177Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4828
label Biography information for Paula Barker more like this